The overall goal of Core A is to provide molecular biology expertise and support for the Program Project by closely interacting with all three Projects and Cores. Core A will construct novel simian-human immunodeficiency virus (SHIV) strains encoding R5 env genes of primary HIV clade C strains (termed SHIVenvC's);isolate, characterize, and sequence env genes from SHIVenvC-infected monkeys during disease progression, and perform diagnostic PCR to assess viral loads.
The Specific Aims are: 1. To insert env genes derived from Zambian infants with rapidly progressive HIV clade C disease into multiply engineered SIVmac239-derived backbones to increase the replicative capacity of the chimeric SHIVenvC strains and to accelerate disease progression in primates. 2. To construct a fully heterologous SHIV based upon an SIV backbone that differs from SIVmac239, such as SIVsmE543-3, and by inserting an R5 HIV clade C env gene that differs from those used to construct the current SHIVenvC isolates. 3. To generate and characterize HIV clade C env mutants and to work closely with Project 1 to assess the molecular evolution of env in SHIVenvC-infected rhesus monkeys during disease progression. 4. To ensure that all experimental monkeys are free of other retrovirus infections prior to enrollment. A highly sensitive DMA PCR assay will be used to monitor for simian retrovirus type D (SRV/D) or simian Ivmphotropic virus type 1 (STLV-1). 5. To monitor all experimental animals in Core C by real-time RT-PCR and DNA PCR for plasma viral RNA or proviral DMA loads, respectively.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program Projects (P01)
Project #
5P01AI048240-10
Application #
8327070
Study Section
Special Emphasis Panel (ZAI1)
Project Start
2011-09-05
Project End
2013-08-16
Budget Start
2011-09-05
Budget End
2013-07-31
Support Year
10
Fiscal Year
2011
Total Cost
$242,808
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Tokatlian, Talar; Kulp, Daniel W; Mutafyan, Andrew A et al. (2018) Enhancing Humoral Responses Against HIV Envelope Trimers via Nanoparticle Delivery with Stabilized Synthetic Liposomes. Sci Rep 8:16527
Ruprecht, Ruth M; Lakhashe, Samir K (2017) Antibody-mediated immune exclusion of HIV. Curr Opin HIV AIDS 12:222-228
Ruprecht, Ruth M (2017) Anti-HIV Passive Immunization: New Weapons in the Arsenal. Trends Microbiol 25:954-956
Schneider, Jeffrey R; Carias, Ann M; Bastian, Arangaserry R et al. (2017) Long-term direct visualization of passively transferred fluorophore-conjugated antibodies. J Immunol Methods 450:66-72
Kulkarni, Viraj; Ruprecht, Ruth M (2017) Mucosal IgA Responses: Damaged in Established HIV Infection-Yet, Effective Weapon against HIV Transmission. Front Immunol 8:1581
Sholukh, Anton M; Watkins, Jennifer D; Vyas, Hemant K et al. (2015) Defense-in-depth by mucosally administered anti-HIV dimeric IgA2 and systemic IgG1 mAbs: complete protection of rhesus monkeys from mucosal SHIV challenge. Vaccine 33:2086-95
Lakhashe, Samir K; Byrareddy, Siddappa N; Zhou, Mingkui et al. (2014) Multimodality vaccination against clade C SHIV: partial protection against mucosal challenges with a heterologous tier 2 virus. Vaccine 32:6527-36
Zhou, Mingkui; Ruprecht, Ruth M (2014) Are anti-HIV IgAs good guys or bad guys? Retrovirology 11:109
Sholukh, Anton M; Byrareddy, Siddappa N; Shanmuganathan, Vivekanandan et al. (2014) Passive immunization of macaques with polyclonal anti-SHIV IgG against a heterologous tier 2 SHIV: outcome depends on IgG dose. Retrovirology 11:8
Bachler, Barbara C; Humbert, Michael; Lakhashe, Samir K et al. (2013) Live-virus exposure of vaccine-protected macaques alters the anti-HIV-1 antibody repertoire in the absence of viremia. Retrovirology 10:63

Showing the most recent 10 out of 77 publications